LncRNA MIR100HG affects the proliferation and metastasis of lung cancer cells through mediating the microRNA-5590-3p/DCBLD2 axis

Sep 21, 2026

Objective: Investigate how long noncoding RNA (lncRNA) MIR100HG regulates lung cancer cell proliferation and metastasis via the microRNA (miR)-5590-3p/DCBLD2 axis. Methods: Quantitative reverse-transcription PCR measured MIR100HG, miR-5590-3p and DCBLD2 levels in tissues and cells; Western blot assessed protein abundance. Functional assays (CCK-8, colony formation, Transwell) evaluated proliferation, migration, and invasion. Luciferase reporter and RNA-immunoprecipitation verified the miR-5590-3p interactions. Results: MIR100HG and DCBLD2 were elevated, while miR-5590-3p was reduced in lung cancer. MIR100HG knockdown or miR-5590-3p upregulation suppressed malignant behaviors; pathway rescue experiments reversed these effects. Conclusion: MIR100HG promotes lung cancer progression by modulating DCBLD2 through miR-5590-3p-dependent binding.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Abstract

Objective

Methods

Results

Conclusion

Introduction

DOI: 10.1002/iid3.1223 ORIGINAL ARTICLE LncRNA MIR100HG affects the proliferation and metastasis of lung cancer cells through mediating the microRNA‐5590‐3p/DCBLD2 axis Shengping Min1,2 | Linxiang Zhang2 | Li Zhang2 | Fangfang Liu2 | Miao Liu1 1Department of Microbiology and Parasitology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China 2Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical College, Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Bengbu, Anhui, China Correspondence Dr. Miao Liu, Department of Microbiology and Parasitology, School of Basic Medical Sciences, Anhui Medical University, No.81 Meishan Rd, Hefei 230000, Anhui, China. Email: [iammiaoliu@163.com](iammiaoliu@163.com) Funding information Science Research Project of Bengbu Medical College, Grant/Award Number: 2022byzd032; Open Resesrch Fund Project of Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Grant/Award Number: HX2023D01; Health Research Program of Anhui, Grant/Award Number: AHWJ2023A20289 Abstract Objective: The aim of this paper is to investigate the effect of long noncoding RNA (lncRNA) MIR100HG on the proliferation and metastasis of lung cancer cells by mediating the microRNA (miR)−5590‐3p/DCBLD2 axis. Methods: RNA levels of MIR100HG, miR‐5590‐3p, and DCBLD2 in lung cancer tissues and cells were detected by quantitative reverse‐transcription polymerase chain reaction, and protein level was assessed by Western blot. Effects of MIR100HG or miR‐5590‐3p on proliferation, migration, and invasion of lung cancer cells were detected by Cell Counting Kit‐8, colony formation, and Transwell assays. Luciferase reporter assay and RNA‐immunoprecipitation assay confirmed the target relationship between miR‐5590‐3p and MIR100HG or DCBLD2 . Results: MIR100HG and DCBLD2 were highly expressed, while miR‐5590‐3p was lowly expressed in lung cancer tissues and cells. Silencing MIR100HG or upregulating miR‐5590‐3p impeded lung cancer cell proliferation, migration, and invasion. MIR100HG could up‐regulate DCBLD2 by sponging miR‐5590‐ 3p. Downregulation of miR‐5590‐3p partly overturned the suppressive effect of silencing MIR100HG on lung cancer cell proliferation and metastasis, andoverexpression of DCBLD2 also reversed the effect of overexpression of miR‐5590‐3p on lung cancer cell proliferation and metastasis. Conclusion: LncRNA MIR100HG promotes lung cancer progression by targeting and negatively regulating DCBLD2 through binding with miR‐5590‐3p. KEYW OR DS DCBLD2, lung cancer, lncRNA MIR100HG, metastasis, miR‐5590‐3p, proliferation | Shengping Min and Linxiang Zhang contributed equally to this manuscript. | | --- | | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. | Immun Inflamm Dis. 2024;12:e1223 . [https://doi.org/10.1002/iid3.1223](https://doi.org/10.1002/iid3.1223) [wileyonlinelibrary.com/journal/iid3](wileyonlinelibrary.com/journal/iid3) 1 of 12 1 | INTRODUCTION Lung cancer is a frequently diagnosed tumor and a chief reason for cancer‐related deaths around the world, ad there are an estimated 2 million suffers and 1.76 million deaths annually.1 Lung cancer involves diverse treatment modalities, consisting of surgery, interventional radiology, radiotherapy, palliative care, as well as systemic therapies (immunotherapy, chemotherapy, and targeted agents) .2 Centralized clinical management of postsurgical lung cancer patients by nurses remains a priority, regardless of the technique used.3 Lung cancer tumors are allocated into two histological categories, consisting of non‐small‐cell lung carcinoma (NSCLC) and small

FAQs

What is the main objective of this study?

To determine how lncRNA MIR100HG affects lung cancer cell proliferation and metastasis through mediating the miR-5590-3p/DCBLD2 axis.

How were RNA and protein levels measured?

RNA levels of MIR100HG, miR-5590-3p, and DCBLD2 were measured by quantitative reverse-transcription PCR, and DCBLD2 protein levels were assessed by Western blot.

What do the results show about MIR100HG, miR-5590-3p, and DCBLD2 in lung cancer?

MIR100HG and DCBLD2 were highly expressed, whereas miR-5590-3p was lowly expressed in lung cancer tissues and cells.

Sep 21, 2026

Uploaded by Ava Thompson